Epilepsy

Neurology·MeSH: Epilepsy

Prevalence

700.0 / 100K

Incidence

48.0 / 100K/yr

51 drugs in development·37 companies·19 clinical trials

Drug Pipeline by Phase

Approved(12)

Drug	Company
carbamazepine	ANI PHARMACEUTICALS INC (ANIP)
Diastat authorized generic	Bausch Health Companies Inc. (BHC)
evo cortical electrode	NeuroOne Medical Technologies Corporation (NMTC)
evo seeg electrode	NeuroOne Medical Technologies Corporation (NMTC)
felbamate	ANI PHARMACEUTICALS INC (ANIP)
lamotrigine	Teva Pharmaceutical Industries Limited (TEVA)
levetiracetam	Mylan II B.V. (MYL)
levetiracetam in	NEXUS BIOPHARMA INC (NEXS)
onerf ablation system	NeuroOne Medical Technologies Corporation (NMTC)
topiramate	DR REDDYS LABORATORIES LTD (RDY)
topiramate	Teva Pharmaceutical Industries Limited (TEVA)
Trokendi XR	SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Phase 3(13)

Drug	Company
20 mg/day vormatrogine for 12 weeks	Praxis Precision Medicines, Inc. (PRAX)
30 mg/day vormatrogine for 12 weeks	Praxis Precision Medicines, Inc. (PRAX)
40 mg/day vormatrogine for 12 weeks	Praxis Precision Medicines, Inc. (PRAX)
ANAVEX®2-73	ANAVEX LIFE SCIENCES CORP. (AVXL)
AXS-17	Axsome Therapeutics, Inc. (AXSM)
gene therapies for dravet syndrome	ZOGENIX, INC. (ZGNX)
rap-219	Rapport Therapeutics, Inc. (RAPP)
rns system	Neuropace Inc. (NPCE)
soticlestat	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
soticlestat	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
Vormatrigine	Praxis Precision Medicines, Inc. (PRAX)
vormatrogine	Praxis Precision Medicines, Inc. (PRAX)
xen1101	Xenon Pharmaceuticals Inc. (XENE)

Phase 2(3)

Drug	Company
BMB-101	BRIGHT MINDS BIOSCIENCES INC. (DRUG)
darigabat	Cerevel Therapeutics Holdings, Inc. (CERE)
ykp3089	KYTO TECHNOLOGY & LIFE SCIENCE, INC. (KBPH)

Phase 1(3)

Drug	Company
BHV-7000	Biohaven Ltd. (BHVN)
nbi-921355	Xenon Pharmaceuticals Inc. (XENE)
xcopri	KYTO TECHNOLOGY & LIFE SCIENCE, INC. (KBPH)

Preclinical(13)

Drug	Company
ads-4101	Adamas Pharmaceuticals Inc (ADMS)
aeol 11207	AEOLUS PHARMACEUTICALS, INC. (AOLS)
aevi-004	AEVI GENOMIC MEDICINE, INC. (GNMX)
ART12.11	ARTELO BIOSCIENCES, INC. (ARTL)
BAER-101	AVENUE THERAPEUTICS, INC. (ATXI)
cannabidophorol pro	INNOVATION1 BIOTECH INC. (GMVP)
Cannabis Genomic Study	WEED, INC. (BUDZ)
cannabis-derived products	One World Products, Inc. (OWPC)
CBS104	Harmony Biosciences Holdings, Inc. (HRMY)
parenteral-delivered formulations	NEXIEN BIOPHARMA, INC. (NXEN)
prtt-200	PROTECT PHARMACEUTICAL CORP (PRTT)
supera-cbd	Q/C TECHNOLOGIES, INC. (QCLS)
trv045	TREVENA INC (TRVN)

Unknown(3)

Drug	Company
Cannabis Genomic Study (Sangre AT, LLC)	WEED, INC. (BUDZ)
sodium valporate	Sanofi (SNY)
sodium valporate	Sanofi (SNYNF)

Phase 1/Phase 2(2)

Drug	Company
aav9-hsyn1-migrik2	uniQure N.V. (QURE)
amt-260	uniQure N.V. (QURE)

Phase 2/Phase 3(2)

Drug	Company
mycophenolate sodium	Sanofi (SNY)
opakalim	Biohaven Ltd. (BHVN)

BioSniper tracks 51 drugs in development for Epilepsy across 37 companies.

There are 19 clinical trials targeting Epilepsy tracked by BioSniper.

The estimated prevalence of Epilepsy is approximately 700.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.